Axsome Therapeutics, Inc.
EIR issued July 15, 2021 · New York, New York
- Inspection
- Jun 21 – Jul 1, 2021
- Investigator
- Geoffrey K. Kilili
- Pages
- 22
- FEI number
- 3018815311
In short: This is FDA's Establishment Inspection Report (EIR) for Axsome Therapeutics, Inc. in New York, New York (FEI 3018815311), covering the inspection of Jun 21 – Jul 1, 2021. It is the investigator's full narrative of what they examined, who they spoke to and what they found. The investigator was Geoffrey K. Kilili.
Inside this inspection report
The investigator's narrative
The full inspection report: what the investigator looked at, who they spoke to and what they found, in their own words.
Get the full EIRThis inspection in context
Geoffrey K. Kilili
7 documents · 2021–2025
Cites 211.22 (responsibilities of quality control unit) more than any other section. Most of their documents are for sites in Ohio.
The firmAxsome Therapeutics, Inc. history
The site's inspection history, in date order.
Similar documentsMore eirs
Browse other documents of this type.
Questions about this EIR
Who inspected Axsome Therapeutics, Inc.?
Geoffrey K. Kilili is named on this EIR, for the inspection of Jun 21 – Jul 1, 2021. Each investigator has a profile showing what they cite most.
When was Axsome Therapeutics, Inc. inspected by FDA?
The inspection ran Jun 21 – Jul 1, 2021.
How do I get the full EIR for Axsome Therapeutics, Inc.?
Download the original PDF from FDA Intel for $550, with no subscription. You also get an invoice PDF with the order.